Literature DB >> 21647162

ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.

L Amrein, Z Rachid, B Jean-Claude, D Soulières, R Aloyz, L Panasci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21647162      PMCID： PMC3846538          DOI： 10.1038/leu.2011.110

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

Review 1.  The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.

Authors:  Deepa Sampath; William Plunkett
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

2.  A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.

Authors:  Jonathan Hebb; Sarit Assouline; Caroline Rousseau; Pierre Desjardins; Stephen Caplan; Merrill J Egorin; Lilian Amrein; Raquel Aloyz; Lawrence Panasci
Journal:  Cancer Chemother Pharmacol       Date:  2010-12-01       Impact factor: 3.333

Review 3.  Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

Authors:  Trevor W Dennie; Jill M Kolesar
Journal:  Clin Ther       Date:  2009       Impact factor: 3.393

4.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Authors:  Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

5.  Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties.

Authors:  Zakaria Rachid; Athanasia Katsoulas; Christopher Williams; Anne-Laure Larroque; James McNamee; Bertrand J Jean-Claude
Journal:  Bioorg Med Chem Lett       Date:  2007-05-24       Impact factor: 2.823

6.  A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci.

Authors:  Enriqueta Riballo; Martin Kühne; Nicole Rief; Aidan Doherty; Graeme C M Smith; María-José Recio; Caroline Reis; Kirsten Dahm; Andreas Fricke; Andrea Krempler; Antony R Parker; Stephen P Jackson; Andrew Gennery; Penny A Jeggo; Markus Löbrich
Journal:  Mol Cell       Date:  2004-12-03       Impact factor: 17.970

7.  Imatinib sensitizes CLL lymphocytes to chlorambucil.

Authors:  R Aloyz; K Grzywacz; Z-Y Xu; M Loignon; M A Alaoui-Jamali; L Panasci
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

8.  Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase.

Authors:  Zakaria Rachid; Athanasia Katsoulas; Fouad Brahimi; Bertrand Jacques Jean-Claude
Journal:  Bioorg Med Chem Lett       Date:  2003-10-06       Impact factor: 2.823
  8 in total
  1 in total

1.  Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.

Authors:  May Shawi; Tsz Wai Chu; Veronica Martinez-Marignac; Y Yu; Sergei M Gryaznov; James B Johnston; Susan P Lees-Miller; Sarit E Assouline; Chantal Autexier; Raquel Aloyz
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.